Trials / Completed
CompletedNCT01032772
ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy
ChoicesPlus: Preconception Approach to Reducing Alcohol- and Tobacco-Exposed Pregnancy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 261 (actual)
- Sponsor
- University of Texas at Austin · Academic / Other
- Sex
- Female
- Age
- 18 Years – 44 Years
- Healthy volunteers
- Accepted
Summary
Choices Plus, a randomized controlled study, will determine the efficacy of the Project CHOICES intervention plus a referral to an evidence-based smoking cessation program in reducing the risk of alcohol- and tobacco-exposed pregnancies.
Detailed description
This randomized controlled study will examine the effect of the ChoicesPlus intervention compared to Treatment as Usual (TAU) in: reducing alcohol use below established risk levels; increasing consistent use of effective contraception; increasing engagement in smoking cessation treatment and increasing smoking cessation. In addition, our examination of the incremental costs of the ChoicesPlus intervention (e.g., staff time, materials, administrative services, total medical charges pre- and post-intervention) will provide a basis for future cost/benefit analyses that will inform policymakers and healthcare organizations of the potential benefits of implementing ChoicesPlus. Results from this study will inform and advance future efforts in the service of promoting healthy prenatal behavior and reducing the prevalence of alcohol and tobacco-exposed pregnancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Choices Plus | Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions. |
| BEHAVIORAL | Information | Participants are provided with informational materials about healthy lifestyle and local resources. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2009-12-15
- Last updated
- 2015-11-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01032772. Inclusion in this directory is not an endorsement.